Race Oncology Past Earnings Performance
Past criteria checks 0/6
Race Oncology's earnings have been declining at an average annual rate of -27.6%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been growing at an average rate of 64.9% per year.
Key information
-27.6%
Earnings growth rate
-16.3%
EPS growth rate
Biotechs Industry Growth | 9.6% |
Revenue growth rate | 64.9% |
Return on equity | -75.5% |
Net Margin | -345.2% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?
Aug 26We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully
May 10We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate
Jan 23Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation
Oct 05Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth
Jun 20We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow
Feb 17Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation
Oct 14Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation
Apr 01We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely
Apr 05What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?
Mar 01How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?
Jan 07Revenue & Expenses Breakdown
How Race Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 4 | -14 | 4 | 11 |
31 Mar 24 | 5 | -12 | 4 | 11 |
31 Dec 23 | 6 | -11 | 3 | 11 |
30 Sep 23 | 4 | -11 | 3 | 9 |
30 Jun 23 | 3 | -10 | 3 | 8 |
31 Mar 23 | 2 | -10 | 3 | 7 |
31 Dec 22 | 1 | -11 | 3 | 7 |
30 Sep 22 | 1 | -11 | 4 | 6 |
30 Jun 22 | 1 | -11 | 4 | 6 |
31 Mar 22 | 1 | -10 | 4 | 5 |
31 Dec 21 | 1 | -9 | 4 | 4 |
30 Sep 21 | 1 | -8 | 4 | 3 |
30 Jun 21 | 0 | -6 | 3 | 2 |
31 Mar 21 | 0 | -5 | 3 | 2 |
31 Dec 20 | 0 | -4 | 3 | 1 |
30 Sep 20 | 0 | -4 | 2 | 1 |
30 Jun 20 | 0 | -4 | 2 | 1 |
31 Mar 20 | 0 | -3 | 2 | 1 |
31 Dec 19 | 0 | -3 | 1 | 1 |
30 Sep 19 | 0 | -3 | 1 | 1 |
30 Jun 19 | 0 | -4 | 2 | 1 |
31 Mar 19 | 0 | -4 | 2 | 1 |
31 Dec 18 | 0 | -5 | 3 | 1 |
30 Sep 18 | 0 | -6 | 4 | 1 |
30 Jun 18 | 0 | -6 | 4 | 1 |
31 Mar 18 | 0 | -6 | 4 | 1 |
31 Dec 17 | 0 | -6 | 3 | 1 |
30 Sep 17 | 0 | -5 | 3 | 1 |
30 Jun 17 | 0 | -4 | 3 | 1 |
31 Mar 17 | 0 | -3 | 2 | 1 |
31 Dec 16 | 0 | -2 | 2 | 0 |
30 Sep 16 | 0 | -1 | 1 | 0 |
30 Jun 16 | 0 | 0 | 0 | 0 |
31 Mar 16 | 0 | 0 | 0 | 0 |
31 Dec 15 | 0 | 0 | 0 | 0 |
30 Sep 15 | 0 | 0 | 0 | 0 |
30 Jun 15 | 0 | 0 | 0 | 0 |
Quality Earnings: RAC is currently unprofitable.
Growing Profit Margin: RAC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RAC is unprofitable, and losses have increased over the past 5 years at a rate of 27.6% per year.
Accelerating Growth: Unable to compare RAC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RAC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.6%).
Return on Equity
High ROE: RAC has a negative Return on Equity (-75.47%), as it is currently unprofitable.